Publications by authors named "Zhenya Senyak"
Background: Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, have severe function-limiting symptom burden that is experienced by the majority of patients. Previous studies have suggested that depression may be present in over a quarter of MPN patients, but to date no studies have evaluated the relationship between depression and other variables such as symptoms.
Methods: A 70-item internet based survey regarding fatigue and mood symptoms was developed by a multidisciplinary team of MPN investigators, patients and patient advocates including Patient Health Questionnaire and the Myeloproliferative Neoplasm Symptom Assessment Form was completed by over 1300 patients with MPN diagnosis.
Article Synopsis
- - The study investigates how gender affects the symptoms and complications of myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and myelofibrosis, involving 2,006 patients.
- - Findings reveal that females are more likely to experience severe and frequent symptoms compared to males, despite similar quality of life scores, with women particularly reporting worse abdominal and microvascular symptoms.
- - Males, on the other hand, are more likely to have polycythemia vera and experience complications such as thrombocytopenia and greater red blood cell transfusion requirements, along with shorter disease duration.
Background: Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms.
View Article and Find Full Text PDFBackground: Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs.
Methods: A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center.
Article Synopsis
- Polycythemia vera (PV) is a condition linked to serious health issues and unpleasant symptoms, and JAK inhibitor therapy has shown promise for patients who have previously used hydroxyurea (HU) and experience symptoms like splenomegaly.
- A study evaluated 1,334 PV patients to investigate how previous HU use, phlebotomy needs, and splenomegaly contribute to symptom severity.
- Findings revealed that each of these factors is associated with a significant symptom burden, and having more than one feature increases the severity of symptoms, highlighting that patients with any of these issues experience considerable discomfort.